Gouty Arthritis Pipeline Review, H2 2016, latest research study provides in depth analysis on Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) targeted pipeline therapeutics.
Gouty Arthritis therapeutics industry report provides comprehensive information on the therapeutics under development for Gouty Arthritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Gouty Arthritis and features dormant and discontinued projects.
Gout is a type of arthritis where swelling and severe pain develops in joints, especially at the base of the big toe. Gout occurs when uric acid builds up in blood and causes inflammation in the joints. Symptoms include sudden onset of joint pain, joint swelling, heat in the affected area and joint redness. Risk factors include obesity, high alcohol intake, injury to a joint, long-standing kidney disease and high intake of foods rich in purines.
Browse more detail information about Gouty Arthritis market report at: http://www.absolutereports.com/gouty-arthritis-gout-pipeline-review-h2-2016-10435019
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key players in Gouty Arthritis – Pipeline Review, H2 2016:
- Allena Pharmaceuticals, Inc.
- AstraZeneca Plc
- C&C Research Laboratories
- Cell Medica Limited
- Immune Response BioPharma, Inc.
- IOmet Pharma
- Jiangsu Hengrui Medicine Co., Ltd.
- LG Life Science LTD.
Get a PDF Sample of Gouty Arthritis Market Research Report at: http://www.absolutereports.com/enquiry/request-sample/10435019
Drug Profiles of Included in Gouty Arthritis Therapeutics Development Market Report
And other drug profiles
Have any query? ask our expert @ http://www.absolutereports.com/enquiry/pre-order-enquiry/10435019
Key Topics Covered:
2.Gouty Arthritis Overview
3.Gouty Arthritis Therapeutics Development
4.Pipeline Products for Gouty Arthritis – Overview
5.Pipeline Products for Gouty Arthritis – Comparative Analysis
6.Gouty Arthritis – Therapeutics under Development by Companies
7.Gouty Arthritis – Therapeutics under Investigation by Universities/Institutes
8.Gouty Arthritis Products Glance
9.Late Stage Products
10.Clinical Stage Products
11.Early Stage Products
12.Gouty Arthritis – Products under Development by Companies
13.Gouty Arthritis – Products under Investigation by Universities/Institutes
14.Gouty Arthritis – Companies Involved in Therapeutics Development
15.Gouty Arthritis Drug Profiles
16.Gouty Arthritis Dormant Projects
17.Gouty Arthritis Discontinued Products
18.Gouty Arthritis Featured News & Press Releases
Oct 26, 2016: Selecta Biosciences Initiates Phase 2 Clinical Trial of SEL-212, First Non-Immunogenic Biologic in Development for Treatment of Gout
Jun 27, 2016: TWi Biotechnology Announces Last Patient Enrolled in Phase 2 Study of AC-201CR for Gout Treatment
May 10, 2016: Revive Therapeutics Provides Clinical and Corporate Update
Apr 21, 2016: European patent granted on new formulation of Kineret (anakinra)
Mar 23, 2016: Sobi to initiate clinical development programs in acute gout and Still disease, and receives US patent on new formulation for Kineret (anakinra)
Dec 24, 2015: TWi Biotechnology Reports Positive Interim Results from AC-201 CR Phase 2 Proof-of-Concept Study in Gout Patients
Dec 23, 2015: Selecta Biosciences Announces Dosing of First Patient in Phase 1b Clinical Trial of SEL-212, Designed to be the First Non-Immunogenic Biologic Treatment for Gout
Oct 19, 2015: MonoSol Rx Leadership Presents Data Supporting PharmFilm Technology Effective for Oral Peptide Delivery
Sep 30, 2015: Revive Therapeutics Announces Positive Interim Results From Phase 2a Study of REV-002 in the Treatment of Acute Gout Flares
Jun 30, 2015: New Indication for Teijin Pharma’s Febuxostat in Europe
Get Discount on Gouty Arthritis Market Research Report at: http://www.absolutereports.com/enquiry/request-discount/10435019
List of Figures
- Number of Products under Development for Gouty Arthritis (Gout), H2 2016
- Number of Products under Development for Gouty Arthritis (Gout) – Comparative Analysis, H2 2016
- Number of Products under Development by Companies, H2 2016
- Comparative Analysis by Clinical Stage Development, H2 2016
- Comparative Analysis by Early Stage Products, H2 2016
- Assessment by Monotherapy Products, H2 2016
- Number of Products by Top 10 Targets, H2 2016
- Number of Products by Stage and Top 10 Targets, H2 2016
- Number of Products by Top 10 Mechanism of Actions, H2 2016
- Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
- Number of Products by Routes of Administration, H2 2016
- Number of Products by Stage and Routes of Administration, H2 2016
- Number of Products by Molecule Types, H2 2016
- Number of Products by Stage and Molecule Types, H2 2016
About Absolute Report:
Absolute Reports is an upscale platform to help key personnel in the business world in strategizing and taking visionary decisions based on facts and figures derived from in depth market research. We are one of the top report resellers in the market, dedicated towards bringing you an ingenious concoction of data parameters.
Mr. Ameya Pingaley
+1-408 520 9750
Email – firstname.lastname@example.org